In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.
INTRODUCTION
The average percentage of objective response is around 15%, and its duration does not exceed 6 months [3] . Generally speaking, the drug is well tolerated, with the chief adverse events being the loss of appetite, nausea, emesis and suppression of the bone marrow function. Despite the lack of prospective randomized controlled clinical studies comparing dacarbazine to placebo, it still remains the most important drug in melanoma "classical chemotherapy" and comparator for the majority of new study drugs under clinical evaluation. Moreover, it is often the only therapeutic option available, as other forms of treatment are disqualified.
Temozolomide, vinca alkaloids, platinum analogues, taxanes or nitrosourea derivatives have not been proven to extend the mean OS as compared to dacarbazine. Hence, they can be administered as subsequent lines of chemotherapy or as components of multi-drug schemes.
Additionally, multi-drug chemotherapy is significantly more toxic than DTIC, offering a higher percentage of response to treatment, but with no clear benefit as regards the overall survival [4] . The mean OS was 13.2 and 9.6 months respectively [7] . Additionally, the drug is active in cases of CNS metastases. In the MO25653 study, the mean OS in that group of patients whose prognosis is especially poor, amounted to 5.3 months [8].
MOLECULAR TARGETED THERAPIES
Vemurafenib is available as 240 mg tablets. Recommended dosage is 960 mg twice a day. In case of adverse events, the dose may be reduced to 480 mg twice daily. Major adverse events include hepatotoxicity, arthralgia, fatigue, dermal toxicity (rash, photophobia, pruritus), secondary skin neoplasms, e.g. squamous-cell carcinoma, nausea, and alopecia. Clinical practice has seen early response to treatment, frequently leading to a spectacular regression of even highly advanced lesions. However, de- 
IMMUNOTHERAPY
The origins of contemporary oncological immunotherapy go back to the end of the 1950s. Then, the concept of immunological surveillance was formulated by Burnet and Thomas, based on the premise that cancer cells are eliminated by the body's immune system. According to the theory, cancer develops when a part of the population of mutant cells ceases to be subject to immunological surveillance [14] . An indirect proof that the hypothesis is correct is the increased incidence of oncological diseases among people with compromised immune systems. Nowadays, the hypothesis has been modified to assume that there is a continuous interaction between the neoplasm and the immune system, and even if the body fails to defeat the tumour, its development and progression largely depend on the reactivity of the immune system [15] . Thus, the immune system comprises mechanisms inhibiting its excessive stimulation, with one of them being the CTLA-4 molecule found on the surface of the activated T cells. It exhibits a much higher affinity to the B7 molecule than the CD28 molecule. Once CTLA-4 binds with B7, the co-stimulation signal is interrupted, and the immune response is inhibited [16] . Ipilimumab is a human anti-CTLA-4 antibody. By binding with this molecule (on the surface of the T lymphocytes), it prevents the immune system response inhibition.
The registration trial compared ipilimumab with the gp100 vaccine. Mean OS was 10.1 vs. 6.4 months respectively [17] .
The CA184-024 phase III trial, on the other hand, compared combined therapy involving ipilimumab and dacarbazine with efficacy of dacarbazine monotherapy. Mean OS was 11 vs. 9 months respectively [18] . The results obtained, even though statistically significant, do not appear to be a breakthrough at face value. However, there is a group of ipilimumab-treated patients (around 20%) who achieve long-term benefits from treatment [19] . Some even suggest that there may be cases of complete recovery from advanced melanoma. Ipilimumab's entirely new mechanism of action also requires a set of different criteria to assess response to treatment. The assessment should not be performed earlier than 12 weeks into therapy, and regression of lesions may occur after an initial period of pseudo-progression.
That mechanism of action is also related to an entirely new spectrum of adverse events. Turning off the T lymphocyte inhibitory mechanism, ipilimumab may lead to autoimmunity symptoms, including immunological damage to the skin, alimentary tract, endocrine organs, liver, pancreas, kidneys and the nervous system. Severe adverse events (G3/G4) affect a dozen or so per cent of patients, leading to treatment cessation in around 10% of them [20, 21] .
Ipilimumab is dosed at 3 mg/kg and is administered every The most common adverse events included fatigue, rash and diarrhoea [22] .
Pembrolizumab is yet another anti-PD-1 antibody. Ribas et al. recorded 34% of responses to treatment, with 1-year OS amounting to 70% (no mean OS achieved so far) in metastatic melanoma patients treated with pembrolizumab [23] .
It would appear that anti-PD-1 antibodies have lower toxicity and generate earlier response to treatment than ipilimumab.
Moreover, the response is a long-term one, and affects a greater percentage of patients.
In Poland, the two drugs -nivolumab and pembrolizumab -are available only in clinical trial settings.
SUMMARY
Despite a significant progress made in the recent years in the treatment of metastatic/inoperable melanoma, the disease is still associated with poor prognosis. The patients' situation deteriorates due to limited availability of the new classes of 
